Skip Navigation


Annals of Oncology Advance Access originally published online on January 29, 2009
Annals of Oncology 2009 20(4):636-641; doi:10.1093/annonc/mdn683
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/4/636    most recent
mdn683v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moon, H.-G.
Right arrow Articles by Noh, D.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moon, H.-G.
Right arrow Articles by Noh, D.-Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

breast cancer

Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment

H.-G. Moon1, W. Han1,2, J. W. Lee1, E. Ko1, E.-K. Kim1, J.-H. Yu1, S. Y. Kang2, W. K. Moon3, N. Cho3, I.-A. Park4, D.-Y. Oh5, S.-W. Han5, S.-A. Im5 and D.-Y. Noh1,2,*

1 Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Chongno-gu, Seoul
2 Cancer Research Institute, Seoul National University College of Medicine, Seoul
3 Department of Radiology
4 Department of Pathology
5 Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Chongno-gu, Seoul, Korea

* Correspondence to: Dr D.-Y. Noh, Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea. Fax: +82-2-766-3975; E-mail: dynoh{at}plaza.snu.ac.kr

Background: Although recent studies suggest high accuracy of breast magnetic resonance imaging (MRI) in predicting residual tumor extent after neo-adjuvant systemic treatment (NST), its use is still controversial. In this study, we aimed to identify predictive factors of MRI accuracy after NST to determine a subgroup of patients in whom the use of MRI provides best additional benefit.

Materials and methods: Clinicopathologic and molecular profiles of breast cancer patients were investigated and their relationships with MRI accuracy were analyzed.

Results: From January 2006 to February 2008, 195 patients received NST and preoperative MRI. In overall, MRI predicted residual tumor extent with higher accuracy than ultrasonography. Triple-negative (TN) tumors showed highest correlation between MRI-measured and pathologic tumor size (r = 0.781) when compared with other subtypes. Multivariate analysis showed age and HER2 expression status as independent factors predicting MRI accuracy. When patients were classified based on their age and HER2 status, relatively older patients (>45) with HER2-negative tumors showed highest MRI accuracy. This finding was further validated using an independent cohort of 63 consecutive patients.

Conclusion: Age and HER2 status independently affected MRI accuracy after NST. This observation may guide more tailored approach in using MRI in breast cancer patients undergoing NST.

Key words: age, breast cancer, HER2 gene, magnetic resonance imaging, neo-adjuvant treatment

Received for publication September 18, 2008. Accepted for publication September 24, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, and N. Harbeck
Triple-negative breast cancer--current status and future directions
Ann. Onc., December 1, 2009; 20(12): 1913 - 1927.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.